QUALITY OF LIFE RESEARCH is a prestigious academic journal published by SPRINGER, specializing in the interdisciplinary field of public health, with a particular focus on quality of life and health-related outcomes. With an impressive impact factor that places it in the Q1 quartile of the Public Health, Environmental and Occupational Health category, this journal has been a significant contributor to the literature since its inception in 1992. In 2023, it was ranked #111 out of 665 in the Scopus rankings, reflecting its critical role in advancing research that informs public policy and health practices. Located in the Netherlands, the journal not only disseminates high-quality research but also promotes a deeper understanding of the factors influencing individual and community well-being. Despite not being an open-access journal, it offers a variety of subscription options to ensure accessibility for researchers, professionals, and students alike. By fostering a collaborative platform for innovative research and comprehensive reviews, QUALITY OF LIFE RESEARCH continues to enhance scholarly discourse and influence real-world health outcomes.

ClinicoEconomics and Outcomes Research is a prestigious open-access journal published by DOVE MEDICAL PRESS LTD, located in New Zealand. Since its inception in 2009, it has established itself as a vital resource for researchers and practitioners in the fields of economics, health policy, and outcomes research. With a commendable impact reflected in its rankings—Q1 in Economics, Econometrics and Finance and Q2 in Health Policy—the journal effectively bridges the gap between economic evaluation and healthcare delivery. This publication is particularly significant for those focused on the economic implications of health interventions, policy analysis, and decision-making processes in healthcare systems. As an open-access journal, ClinicoEconomics and Outcomes Research ensures that its valuable content is widely accessible, enhancing knowledge dissemination and fostering collaboration among academia, industry, and policymakers. With an ambition to contribute to the improvement of health outcomes through rigorous research, it invites submissions that address the multifaceted challenges facing the economics of healthcare today. Join the scholarly dialogue where innovative ideas in health economics thrive!

Global & Regional Health Technology Assessment (ISSN: 2284-2403; E-ISSN: 2283-5733) is an esteemed open-access journal published by ABOUTSCIENCE SRL, dedicated to the dissemination of research in the field of health technology assessment on a global and regional scale. Since its inception in 2014, this journal has focused on the critical evaluation of health technologies, providing invaluable insights into their efficacy, cost-effectiveness, and impact on healthcare systems. With an increasing emphasis on public health and policy implications, the journal encourages interdisciplinary research that bridges gaps between technological innovations and health outcomes. Despite its relatively recent establishment, it has made significant inroads with Scopus rankings reflecting the growing importance of health technology assessment in global health discourse. The journal welcomes contributions from researchers, professionals, and students, inviting them to engage in discussions that shape the future of health technology, with the aim of informing stakeholders and policymakers worldwide.

PHARMACOECONOMICS, published by ADIS INT LTD, is a prestigious international journal dedicated to disseminating research in the fields of health policy, pharmacology, and public health. With an impressive impact factor and a solid Q1 ranking across its relevant categories, this journal plays a crucial role in shaping policy decisions, optimizing health resources, and enhancing pharmacoeconomic evaluations globally. The journal not only targets researchers and professionals but also serves as an invaluable resource for students striving to understand the economic implications of pharmaceutical care. Operating since 1992 and continuously evolving through 2024, PHARMACOECONOMICS invites contributions that address the complexities of drug expenditure, health outcomes, and public health implications, thereby fostering informed decision-making in healthcare systems. Readers can explore cutting-edge studies and analyses aimed at balancing cost-effectiveness with clinical effectiveness, making this journal a cornerstone for stakeholders invested in the future of health economics.

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

Expert Review of Pharmacoeconomics & Outcomes Research is a leading journal published by TAYLOR & FRANCIS LTD, focusing on the critical intersection of pharmacoeconomics and healthcare outcomes. Established in 2001, the journal has been a key resource for researchers and professionals in the fields of health policy, medicine, and pharmacology, consistently ranked in the top quartile of these categories for its influential insights. With an ISSN of 1473-7167 and an E-ISSN of 1744-8379, it delivers cutting-edge research that informs healthcare decisions and policy frameworks. The journal's rigorous peer-review process ensures the publication of high-quality, impactful articles that address contemporary challenges and advancements in pharmacoeconomic evaluations. As of 2023, it boasts a commendable ranking of #106 in Health Policy and #124 in Pharmacology, affirming its relevance and contribution to the field. Despite being a subscription-based journal, the strength of its content makes it an invaluable tool for researchers and practitioners aiming to enhance patient outcomes and optimize resource allocation in healthcare systems.

Farmeconomia-Health Economics and Therapeutic Pathways is a pioneering journal within the field of health economics, dedicated to exploring the intersections of health policy, therapeutics, and economic evaluations. Published by SEED MEDICAL PUBLISHERS, this Open Access journal has been at the forefront of advancing knowledge since 2012, ensuring that vital research is readily accessible to a global audience without subscription barriers. The journal aims to facilitate the dissemination of insightful studies, systematic reviews, and theoretical discussions that determine the cost-effectiveness of therapeutic options, ultimately guiding evidence-based healthcare decisions. Based in *Torino, Italy*, this journal is committed to serving researchers, healthcare professionals, and students who are eager to contribute to and stay updated on the latest developments in health economics and policy implementation. With its broad-ranging scope and dedication to quality research, Farmeconomia stands as an essential resource for anyone engaged in the complex dynamics of health systems and their economic implications.

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE is a leading academic journal published by Cambridge University Press, specializing in the critical evaluation of healthcare technologies and their impact on health policy. Established in 1970, it has gained recognition within the field, currently holding a prestigious Q2 ranking in Health Policy, with a commendable position of #89 out of 310 in the Scopus rankings, placing it in the 71st percentile. The journal serves as an essential platform for researchers, professionals, and students interested in the intersection of technology and health care, facilitating the dissemination of innovative research findings and practical assessments that inform policy-making and improve health outcomes. With a focus on advancing knowledge from 1985 to 2024, the journal's content remains relevant and impactful. Though not open access, it offers subscription-based access to a wealth of articles that contribute to shaping the future of healthcare technology assessment.

Cost Effectiveness and Resource Allocation is a premier open-access journal published by BMC, dedicated to advancing the field of health policy and economics. Since its inception in 2003, the journal has provided a platform for researchers, policymakers, and healthcare professionals to disseminate crucial findings and insights relevant to cost-effectiveness analyses and resource allocation strategies. With an increasing impact factor and ranking within the Q2 category of health policy journals, it ranks #138 out of 310 in Scopus, placing it in the 55th percentile among its peers. The journal aims to facilitate knowledge exchange that can transform health policy and improve healthcare delivery through rigorous research, evaluation, and dialogue. Open access since its establishment, it ensures that critical findings are available to a global audience, thereby enhancing the impact and reach of its published works.

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.